Interest in developing combination products to overcome drug resistance and treat complex diseases is growing. However, ambiguity remains around the value of combination toxicity studies to support combination products. Therefore, the IQ* DruSafe Leadership Group surveyed member companies to evaluate industry experience with combination toxicity strategies, study designs and their impact on clinical development. Twenty companies responded, representing 79 combination programs. Combination toxicity studies were performed based on scientific rationale, regulatory agency request, or expected regulatory requirement. Combination toxicity study designs were varied (eg, group numbers, dose selection rationale and endpoints assessed) with no evidence that any one study design was superior. Studies were perceived as adding value when they fulfilled a regulatory requirement; avoided potential development delays; or when new or exaggerated toxicity or pharmacokinetic interactions were identified. Twelve percent of combination toxicity studies impacted clinical trial designs. The decision to conduct and the design of nonclinical combination toxicity studies should be based on sound scientific judgement with proactive engagement with regulatory agencies. Studies are not warranted when sufficient knowledge (eg, expected pharmacology, known mechanism of action, drug disposition, toxicity profile) is available to proceed safely in clinical development.
Introduction
There is increasing interest within the pharmaceutical industry to develop combination products to overcome drug resistance and treat complex diseases. Regional regulatory guidances (eg, FDA, 2006; EMA, 2005) provided a basis for the subsequent development of harmonized definitive International Conference (Council) on Harmonisation (ICH) guidances containing considerations for combination drug development {ICH M3(R2), 2009 , 2012 ICH S9, 2009 . However, ambiguity remains regarding when combination toxicity studies should be conducted and optimal study designs. studies and the study design considerations based on industry experience would be helpful in developing rational "points-of-consideration" and some consistencies for the design and conduct of these studies. As the pharmaceutical industry's experience with combination products grows, the sharing of outcome data from these studies is critical for understanding how relevant the nonclinical combination toxicity studies have been in informing clinical development of combination products.
To capture the pharmaceutical industry experience in the nonclinical support for development of combination products, a crosspharmaceutical company survey was conducted by the IQ Consortium DruSafe Leadership Group. The survey includes information from both small and large molecule programs across multiple therapeutic areas from 2010 to 2016. Information on device combinations was not in scope. The goal of the survey was to gain insights for the following concepts based on responses from survey participants:
• Rationale for conducting (or not) combination toxicity studies • Impact of regulatory authority interactions • Influence of therapeutic area on combination toxicity program • Types and timing of combination toxicity studies relative to the course of drug development
• Perceived value of the nonclinical combination toxicity studies and their impact on clinical development
Materials and methods
The survey was submitted to member companies of the IQ Consortium DruSafe group. Companies were requested to provide information on the 5 most recent or representative development programs between 2010 and 2016 where two or more compounds were being developed in combination. Drug/device combinations were excluded. The responses from individual companies were kept confidential and were anonymized by an independent third party secretariat (Drinker, Biddle, & Reath LLP) before being provided to the authors.
The initial survey was composed of 15 questions (supplement). Companies were first asked about their involvement in the development of combination products. For companies with combination program experience, the initial questions were designed to generate background information on the program focusing on therapeutic area, class of compounds (small or large molecule), intended use (eg, fixed combination, co-packaged, labeled for use in combination), and stage of development of the individual compounds being combined. Further questions were designed to determine the rationale for why or why not a combination toxicity study was conducted. For programs where a combination toxicity study was conducted, respondents were then asked 1) if they sought regulatory authority advice prior to conducting the combination toxicity study; 2) if a regulatory authority had requested the study; 3) when the combination study was conducted in relationship to the development stage of the combination program; 4) if there was clinical experience with the combined drugs prior to conducting a combination toxicity study; and 5) for any other information on the type of combination study conducted. For programs for which a repeat dose combination toxicity study was conducted, respondents were asked a series of questions regarding the design of the study (study duration, test species, basis for dose selection, number of dose groups, and inclusion of monotherapy arm). Finally, respondents were asked if they felt there was value to the combination toxicity study and why (or why not).
Review of the responses to the initial survey identified a need to better understand the value of the combination toxicity studies; in particular, the impact of the combination toxicity study on the clinical development program. Therefore, respondents who had conducted a combination toxicity study were further queried as to whether the results from the combination toxicity study impacted the clinical trial design or plan and, if so, how the clinical program was impacted (supplement).
For a majority of questions, respondents were asked to select answers from a series of predetermined choices. Responses as to why the combination toxicity study was (or was not) considered of value were described in free text form and, for purposes of collating responses, the authors categorized the individual related responses into general categories. Responses for the rationale for species selection and inclusion of monotherapy arms in the combination repeat dose toxicity study were also in free text format. There were a few individual programs where the response to one question appeared to contradict the response to another question (eg, conflicting responses on whether combination toxicity study had been conducted; conflicting responses on perceived value). In these few cases, the authors made a decision on the most likely intended response when collating the data based on responses to related questions. For instance, if the respondent indicated combination toxicity was not conducted but answers were provided for questions on the rationale for conducting study and study design, the assumption was made that a combination toxicity study was conducted. In addition, there were a few responses where respondents' comments around perceived value conflicted with the predetermined choice selected (i.e., selected "yes" that there was value, but indicated that there was no value in a free-text comment). In these cases, the comment around perceived value was used rather than the predetermined choice selected.
As with all surveys, there were certain limitations that impact the interpretation of the survey. In this survey, respondents were allowed to self-select which 5 programs to provide information on, the only criteria being that the programs were in development between 2010 and 2016 and drug-device combinations were excluded. While many of the respondents provided information on 5 programs (7 of 17; 41%), some companies provided fewer and others provided more (range 1-11 programs/respondent). The survey did not ask how many programs were in development during the reporting timeframe, so it is not possible to determine if responses reflected all programs or only a subset of programs. If only a subset of programs were reported, there is a potential for (un)intentional selection bias by the respondent. In addition, the survey did not ask for the status of the nonclinical and clinical combination studies, and there were a few programs for which either the nonclinical or clinical studies were still ongoing based on comments provided. Therefore, the determination of value for each program may not reflect the same level of nonclinical and clinical information. There may have also been a tendency, based on how the survey was structured, to report on programs for which a repeated dose combination toxicity study was considered or conducted and to overlook early stage combination programs that may have been discontinued based on adverse findings in early pharmacology/efficacy studies. Despite these limitations, the survey provided insight into rationale for conducting combination toxicity studies and the impact of these studies on clinical development programs.
Results and discussion

Demographics
The survey was distributed to 42 member companies. Twenty companies provided responses, of which 3 indicated that they had no experience in the development of combination drugs. Of the remaining 17 companies a total of 79 combination programs were identified across multiple therapeutic areas ( Fig. 1) , of which 57 (72%) conducted non-clinical combination toxicity studies to support the combination program. Anti-infective (22/79; 27.8%), metabolic (19/79; 24.1%) and oncology (11/79; 13.9%) therapies represented the majority of combination programs.
Programs that included at least one small molecule accounted for 86% (68/79) of the combination therapies; the vast majority (75%; 59/ 79) included small molecule only combinations (Fig. 2) . Treatments including combination with a monoclonal antibody were the next most frequently reported and made up 15% (12/79) of the programs. Other combination therapies of lower frequency included a diverse range of drug modalities such as recombinant proteins, peptides and oligonucleotides. The therapies were primarily intended to be administered as fixed formulations (54%; 43/79) or individual drugs labelled for co-use (29%; 23/79).
Rationale for conducting or not conducting combination toxicity studies
The rationales for whether or not to conduct a combination toxicity study were varied, consistent with the complex considerations for the decision to conduct a study. The three most prominent reasons that led companies to initiate combination toxicity studies to support their combination clinical programs included 1) the opinion that the studies were scientifically justified, 2) anticipation that a regulatory agency would require the studies, or 3) a request to conduct the studies by a regulatory agency (United States [US] or ex-US) (Fig. 3) . When studies were initiated based on scientific rationale, there were concerns for potentially overlapping pharmacology or toxicity, new toxicity, or that the outcome of the studies would inform the clinical combination trial design (eg, starting dose, monitoring, etc.). Other infrequent reasons for conducting combination toxicity studies included: 1) the desire to avoid potential delays in the overall development program; 2) past experience with other programs; or 3) interpretation of regulatory guidance with respect to the need for combination toxicity studies.
When combination toxicity studies were not conducted, the decisions behind these actions were also varied. The top reasons why companies believed studies were not needed included the following: 1) there was no indication of overlapping target organ toxicity between individual agents, 2) the risk for ADME interactions, such as drug-drug interactions, was considered to be low, 3) regulatory feedback advised that combination toxicity studies were unnecessary, and 4) the compounds intended for combination had independent mechanisms or pathways, eg, orthogonal pharmacology (Fig. 4) . Collectively, a scientific evaluation of each program had led to the recommendation that nonclinical combination toxicity studies were not needed to support clinical development in these examples. Other less common reasons for not conducting combination toxicity studies were based on combination having been evaluated in pharmacology/efficacy study that included toxicology endpoints, the availability of combination clinical data, or the late development stage of the compounds (compounds with significant clinical experience, eg, Phase 3 or post-market) to be combined (per ICH M3R2 guidance).
Timing of combination toxicity studies in relationship to clinical development
ICH M3R2 guideline and accompanying Q&A document provide some guidance regarding when nonclinical combination testing is required in the course of clinical development, especially with consideration for how much clinical experience exists and the duration and size of the clinical trials proposed; however, timing may be driven by various other factors as well. Only 14 of the 57 programs (25%) conducted a combination toxicity study to support a Phase 1 combination trial (Fig. 5) . Twenty-three programs (40%) conducted a combination study prior to proof of concept Phase 2 combination trials. Thirteen programs (23%) had completed a combination toxicity study to support Phase 3: 5 programs (9%) conducted this study in support of registration; 1 program conducted a study in the postmarketing Phase; and 1 program provided no response for the timing query.
Respondents indicated that in 23 of the 57 programs (40%), clinical data for the combination of the drugs themselves or the drug classes were available prior to conducting the combination toxicity study. Of these 23 programs, only one reported that the combination toxicity study influenced the clinical trial design resulting in increased monitoring. This respondent also indicated that the combination toxicity J. Birkebak et al. Regulatory Toxicology and Pharmacology 102 (2019) [40] [41] [42] [43] [44] [45] [46] study confirmed the predicted (additive) effects of the combination on cardiovascular safety. For 7 of the 57 programs (12%), all individual compounds were prePhase 1 at the time the combination was proposed for clinical testing, suggesting there was no clinical data with the individual compounds prior to initiating the clinical combination program. For the remainder of the programs, some clinical testing with one or both of the individual compounds alone had already been performed based on the stage of development of the individual compounds at the time the combination program was proposed (Fig. 6) .
The influence of clinical indication or therapeutic area on the timing of the combination toxicity studies was also investigated (Fig. 7) . Across most of the therapeutic areas that were highly represented in this survey (ie, anti-infective, metabolic, oncology, cardiovascular and respiratory diseases), the majority of combination toxicity studies were conducted to support Phase 2 or later in development (72%; 34 of 47 programs). However, combination toxicity studies were conducted prior to Phase 1 for oncology (n = 5/7), immunology (n = 2/2), fibrosis (n = 1/1), and ophthalmology (n = 1/1) programs. For the latter 3, this may reflect the reduced risk tolerance for these indications, although the low number of responses impacts the ability to draw strong conclusions. For oncology, the pre-Phase 1 conduct of the studies may be explained by the increase in combining drugs early in developmentas early as first-in-patient trials-or may be due to concerns based on the mechanisms of action given the more highly toxic nature of compounds in this therapeutic area. Additionally, this may also reflect respondents' interpretation of ICH S9 guidance as the combinations going into Phase1 included at least one compound in the combination with no or limited human data (pre-Phase 1 or Phase 1). ICH S9 states "For studies in which at least one of these compounds is in early stage development (i.e., the human toxicity profile has not been characterized), a pharmacology study to support the rationale for the combination should be provided. This study should provide evidence of increased activity in the absence of a substantial increase in toxicity on the basis of limited safety endpoints, such as mortality, clinical signs, and body weight. Based on available information, a determination should be made whether or not a dedicated toxicology study of the combination is warranted."
Regulatory interactions
The survey revealed that regulatory interaction or lack thereof impacted a company's decision to conduct (or not) combination toxicity studies. Regulatory advice was sought for 36 of 79 programs (46%). It was not always possible from the survey responses to determine from which country the regulatory advice originated. While there were no survey questions regarding the type of advice sought and the outcome of the regulatory interaction, it was evident from the responses to related questions and other comments provided that combination toxicity studies were conducted for only 11 of the 36 programs (31%) based on request by health authorities; studies were not conducted for 9 others (25%) based on confirmation by the regulators that the studies were not needed. The outcome of the regulatory interaction for the remaining 16 programs could not be determined based on the survey responses. In total, combination toxicity studies were requested by a regulatory agency for 14 of 57 (25%) programs (for 3 programs, it does not appear that the company proactively sought regulatory advice). Of these 14 programs, 7 companies (50%) were unsuccessful in their proposal to the regulatory agency that a study was not necessary based on scientific rationale. Based on respondent comments provided for two of these 7 programs, the regulatory agency maintained their request for the studies due to concerns regarding synergy of the mechanism of actions for one program and non-mechanistic toxicity for the other program (despite Phase 3 clinical experience with the combination). In neither case did the outcome of the combination toxicity studies impact the clinical programs (i.e., modification of dose, or dosing regimen or a change in clinical monitoring).
In addition, there were 20 programs (20/57 or 35%) where combination toxicity studies were conducted without seeking regulatory advice; of these, 9 studies (45%) were conducted in anticipation of regulatory requirement based either on regulatory feedback on previous programs (3 programs) or on a scientific rationale for conducting the combination toxicity study (6 programs). It appeared that for 11 of the 20 programs (55%), a combination toxicity study was conducted purely based on the expectation of a requirement by the regulatory agencies regardless of any particular basis. The survey did not provide enough in depth data to assess if combination toxicity studies would have indeed been required for all or only a subset of these 11 cases had the company proactively engaged the health authorities.
Combination toxicity study designs
Repeat dose toxicity studies were by far the most common type of combination study conducted; however, the design of the studies varied widely in regards to species selected, number of dose groups and criteria used to select doses. There was no evidence from the survey results that any one study design provided more valuable information over another, though the survey was not specifically crafted to address this point. Studies were likely designed based on unique aspects of the individual combination program (eg, sensitive species, individual agent toxicity, indication, clinical plans, etc.).
For the 57 programs that indicated a combination toxicity study was conducted, 53 programs included a repeated dose combination toxicity study; the majority being of 28-90 days in duration (67%; 38/53). Embryofetal development studies were the next most common type of combination toxicity study conducted (10 programs) followed by cardiovascular safety pharmacology (4), in vitro assays (3), in vitro and/or in vivo genetic toxicity (2), immunotoxicity (1), and juvenile toxicity (1) studies. One respondent indicated that a tolerability and efficacy study was used to support the clinical program.
The majority of programs conducted the repeated dose combination toxicity studies in a single species (79%; 42/53) with rodents and nonrodents being equally represented (21 programs each). For programs where a rationale was provided, species selection was most commonly based on most relevant species (species with overlapping or toxicity of concern), pharmacologically active species, or most sensitive species (species with toxicity at lowest exposure) (Fig. 8) .
Two species (rodent and non-rodent) were evaluated in 11 of the 53 programs that conducted repeated dose combination toxicity studies. In two cases where a rationale was provided, the US Food and Drug Administration (FDA) had requested the combination toxicity studies be conducted in two species. In another case, dose range finding studies of the combination were conducted in both species and the most sensitive species was selected for the definitive repeated dose study. For the remainder of the programs where two species were used, both species were considered necessary either to fully assess the combination (3 programs), as a strategic decision by the company (1 program), or a rationale was not provided (4 programs).
The number of groups included in the study varied from as few as 2 (1 control and 1 treated group) to up to 7 (1 control and multiple treatment groups) (Fig. 9) . Forty-three of the 53 (81%) repeated dose combination toxicity studies included monotherapy arms. For a majority of the 43 programs, monotherapy arms were included for all of the individual agents in the combination; though, on occasion, when significant information was known for one of the agents, a monotherapy arm for that agent was not included. Monotherapy arms were included either at the request of regulatory agency, based on the lack of toxicity data on the individual compounds, or to allow contemporaneous comparison between individual compounds and the combination. For the programs that did not include monotherapy arms, respondents indicated the toxicity of the individual compounds was previously well-characterized.
Selection of dose levels was most frequently based on exposure margin relative to the clinical exposure (51%; 37 of 73 responses [more than one response per program provided in some cases]). A few programs only evaluated doses at a small margin (1 to 2x) to assess safety at clinically relevant doses. Commonly, companies evaluated both lowdose (1-3x exposure margin) and high-dose (10x exposure margin) combinations in the combination toxicity study. In a number of studies (16%; 12 of 73 responses), the maximum tolerated dose (MTD) was used to select the high dose, with one company indicating this was requested by a regulatory agency. Doses were also commonly selected based on minimal toxicity (18%; 13 of 73 responses) or based on the no observed adverse effect level (14%; 10 of 73 responses). Only a few companies indicated the doses were specifically selected to reflect the anticipated ratio of the two compounds in the clinic.
Value of studies
Regardless of why a combination toxicity study was conducted, an important aspect of the survey was to evaluate the perceived value of the combination toxicity study -did the study provide meaningful information? For the 57 programs for which a combination toxicity study was conducted, studies for approximately half were perceived to be without value since no new or unpredicted toxicities were identified. Outcomes were considered largely predictable based on available safety, pharmacology, and drug disposition data with each monotherapy or experience with the classes of drugs. In other cases, the sponsors did not believe there was a strong scientific basis for conducting the studies (no informative value); however, the studies were requested by regulatory authorities.
For the other half of the programs, the nonclinical combination toxicity studies were considered of value for a variety of reasons (Fig. 10) . In many instances, value was perceived despite the lack of new or exaggerated toxicity, as study results gave confidence that there were no new or exaggerated toxicities with the combination. Interestingly, in contrast with opinion noted above, the lack of new or exaggerated toxicities was also a reason why some companies felt the studies did not provide value, which demonstrates the variability in the perception of value. Combination toxicity studies were also considered of value when new or exaggerated effects were observed or the studies Fig. 8 . Rationale for species selection in combination toxicity study. provided important understanding of potential compound interactions. In some cases, value was identified as fulfillment of a regulatory requirement or in anticipation that a study would be required, thus avoiding any potential for a regulatory delay. In 9 programs (25%), new or exaggerated toxicities were identified or confirmed, and in 1 program pharmacokinetic interactions at high doses were seen.
The studies for which new toxicities, unique to the combination, were identified are of particular interest. In each of these cases, combination toxicity studies were conducted based on scientific rationale, for example, knowledge of overlapping mechanisms of action. For an oncology program with two small molecules (both in Phase 2), new toxicities (not disclosed in the survey response) were identified nonclinically, although the respondent implied some uncertainty in the significance of the newly identified toxicities in that tolerability issues were encountered when dual MTDs were employed. In another oncology program with two monoclonal antibodies (pre-Phase 1 and marketed), new toxicities (not disclosed in the survey response) were identified which influenced clinical trial design and/or the label. One respondent reported that for 4 programs targeting metabolic disease all effects were predictable; however, there was an unexpected marginally additive toxicity. These 4 programs were all 2 small molecule combinations in Phase 2.
Of the 57 programs for which a combination toxicity study was conducted, respondents indicated that the nonclinical combination study for 50 (88%) of these programs did not ultimately influence the clinical trial design. The companies for the 7 remaining programs (12%), which spanned the therapeutic areas of neurology, oncology, respiratory, cardiovascular, and metabolic diseases, revealed that the nonclinical combination study provided data that influenced the design of a combination clinical trial (Phase 1 or 2 trials). When further queried as to how a clinical program was influenced, respondents for 4 programs noted that the combination studies drove modification of clinical dose (3 programs-each combination included a marketed and a Phase 1 or 2 investigational compound with the combination entering Phase 1 or 2) or dosing regimen/schedule modification (1 program-two marketed compounds with the combination entering Phase 1). For 3 programs, combination nonclinical studies were the basis for additional monitoring or addition of a safety biomarker. In one case, the combination study relieved concerns about potential drug-drug interactions. All but 2 of the 7 programs that saw an impact were small molecule combinations; 1 of the 2 programs combined a small molecule with a peptide, and the other was a combination of monoclonal antibodies. For the latter biologics combination, the company added that, although the results of the nonclinical combination study caused lowering of the clinical trial doses, the modified clinical doses were considered, in hindsight, too low (presumably for efficacy though not stated in response).
Conclusion
The purpose of the cross-industry survey was to gain insight into the circumstances and considerations driving the initiation of combination toxicity studies; how those studies were conducted; and, significantly, if combination toxicity studies added value to combination drug development programs. From the survey, it was clear that the perception of value depended on the respondent. For instance, the lack of findings in a combination toxicity study was considered valuable by some respondents for the confidence the results provided with regard to safety (eg, the negative predictive value), while others indicated that the lack of findings was not of value. In addition, some respondents considered the studies valuable only because the studies satisfied a regulatory requirement. Some nonclinical combination studies (12%) were deemed to have had an impact on the clinical program (eg, modification of dose, safety monitoring, etc).
From a scientific and animal use perspective (3R's), nonclinical studies should only be conducted when they provide meaningful information with regards to human safety and potential risk. The decision to conduct a combination toxicity study should be made based on a review of all available nonclinical and clinical data for the individual compounds, including information from comparator compounds in the same pharmacological class and information about on and off target pharmacology of the individual compounds, and any available information on the combination (eg, adverse findings in efficacy or pharmacodynamics studies). Combination toxicity studies should be considered when there is insufficient data with the individual compounds to predict the outcome of combining on human safety or there is cause for concern that may potentially impact or inform the clinical program. This is consistent with guidance for advanced cancer (ICH S9 and ICH S9 Q&A), serious and life-threatening conditions (ICH M3(R2) Q&A) and hepatitis C (ICH M3(R2) Q&A). It is proposed that this approach be applied more broadly to all therapeutic indications keeping in mind the overall risk:benefit profile of the combination.
The nonclinical combination study should be designed to address identified safety data gaps that prevent providing adequate guidance to the clinical program. While often this may be a repeated dose toxicity study, there were examples in the survey where in vitro studies or specialized and liability-focused studies (i.e., pharmacology/efficacy, immunotoxicity, CV safety pharmacology, juvenile toxicity) were conducted to support the combination program to address specific concerns either in lieu of or in addition to a repeated dose toxicity study. As an example, for one program where in vitro and in vivo studies were conducted, the respondent indicated that the in vitro study provided more meaningful data for guiding clinical trial design than the in vivo studies. Therefore, the type of study and study design should reflect the needs of the individual program.
The above approach, which incorporates such strategic considerations, requires more proactive engagement with regulatory agencies. This becomes challenging for sponsors given the pressures to rapidly bring promising therapies to market. In fact, there were respondents that indicated combination toxicity studies were done to avoid program delays based on expectation that the study would be required by regulatory agencies. However, some survey respondents indicated that a regulatory agency had advised that the proposed combination toxicity study was not required. Thus, it is likely there are programs where a combination toxicity study was conducted based on expectation the study was a regulatory requirement that would not have been required if the sponsor had proactively discussed the program with the regulatory agency. Early interactions with regulatory agencies regarding the conduct of combination toxicology studies are important and may be the more time-efficient pathway toward development. This may require the pharmaceutical industry and regulatory agencies to develop alternative approaches for more rapid mechanisms for interaction (eg, timely, informal communications rather than schedule-limiting formal meetings). In conclusion, the decision to conduct and the design of nonclinical combination toxicity studies should be based on sound scientific judgement and proactive engagement with regulatory agencies.
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